In a significant move aimed at making oncology treatments more accessible, the Indian government has announced a sharp reduction in the retail prices of 137 anti-cancer medications. Effective November 9, these price cuts are the direct result of a new policy capping trade margins for cancer drugs, a decision that officials expect will provide annual savings of Rs 3,502.31 crore to patients across the country.
This policy shift follows formal recommendations made on October 17 by an expert committee operating under the Directorate General of Health Services (DGHS). Acting on these findings, the Ministry of Chemicals and Fertilisers confirmed that the National Pharmaceutical Pricing Authority (NPPA) has implemented trade margin rationalisation across the identified list of 137 medications. The initiative is designed to curb excessive pricing within the pharmaceutical distribution chain, ensuring that the benefits of the margin cap are passed directly to the end consumer.
The impact of this directive is already visible in the updated filings submitted by the pharmaceutical industry. According to official government data, 76 pharmaceutical companies have submitted revised Maximum Retail Prices (MRPs) for 1,225 distinct formulations. Out of these, 1,031 formulations will see a price reduction. Notably, 600 of these brands have reported price cuts exceeding 50 percent, with the most significant reduction reaching 96.45 percent. Furthermore, the ministry has clarified that any cancer drugs currently in development but not yet launched in the Indian market will also be subject to these trade margin rationalisation rules upon their commercial release.
Several critical treatments have seen dramatic shifts in their market pricing. For instance, the breast cancer capsule Palbociclib (125 mg) by RPG Life Sciences has seen its MRP fall from Rs 40,421.33 to Rs 2,720. Similarly, Abirone, a tablet used for prostate cancer treatment, has had its price reduced from Rs 41,250 to Rs 3,218.23. Other major reductions include the cancer injection Bevacizumab (100 mg), which dropped to Rs 3,318, and Denosumab (60 mg), which is now priced at Rs 6,240. Lupin Limited’s Pertuzumab injection, previously priced at Rs 83,520, has been marked down to Rs 37,358.30.
To ensure the transparency of these changes, the government has mandated that all retailers, dealers, and hospital pharmacies must prominently display the revised price lists on their premises and official websites. State Drug Controllers have been assigned the responsibility of monitoring strict compliance with these new pricing regulations. Consumers are encouraged to verify the updated rates through the official NPPA portal or by using the ‘Pharma Sahi Daam’ mobile application.
The government has also established channels for public feedback regarding the implementation of the new policy. Any instances of overcharging or failure to adhere to the revised MRPs can be reported by consumers through designated official helplines. By enforcing these caps, the Ministry of Chemicals and Fertilisers aims to alleviate the severe financial burden often associated with long-term cancer care in India. This structural change in pharmaceutical pricing is viewed as a key step in improving the affordability of essential medical treatments for patients navigating high-cost health interventions.
Comments